Healthy Volunteers
Conditions
Brief summary
To assess the absorption, distribution, metabolism and excretion of a single dose of 14C labelled AZD1722 in order to define the rates and routes of elimination of AZD1722 and if formed, metabolites.
Interventions
DRUGAZD1722
Single oral dose 15 mg of \[14C\]AZD1722
Sponsors
Ardelyx
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy male volunteers aged ≥50 years * Regular daily bowel movements. * Have a body mass index (BMI) between 18 and 32 kg/m2 (inclusive) and weigh at least 50 kg and no more than 110 kg.
Exclusion criteria
* History of any clinically significant disease or disorder which, in the opinion of the Principal Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study. * History or presence of GI, hepatic or renal disease including GI surgery other than appendectomy or any other condition known to interfere with the ADME of drugs. * Loose stools (Bristol Stool Form Score of 6 or 7) ≥2 days in the past 7 days before admission to the study centre * Use of medications that are known to affect stool consistency and/or GI motility, including fibre supplements, anti-diarrheals, prokinetic drugs, enemas, probiotic medications or supplements; or salt or electrolyte supplements containing sodium, potassium, chloride, or bicarbonate formulations during the past 7 days before admission to the study centre. * Volunteers exposed to radiation levels above background (eg, via X-ray examination) of \>5 mSv in the last year, \>10 mSv over the last 5 years or a cumulative total of \>1 mSv per year of life. * Participation in a previously radiolabelled study within the last 5 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of AZD1722 in plasma samples | Timeframe: Day 1: Predose and up to 120 hours |
| Percentage of radioactive dose recovered in urine and feces | Day 1: Pre-dose and up to 168 hours post-dose |
| Total percentage of radioactive dose recovered from both urine and feces | Day 1: Pre-dose and up to 168 hours post-dose |
| Concentration of total radioactivity in blood and plasma samples | Timeframe: Day 1: Predose and up to 120 hours |
Secondary
| Measure | Time frame |
|---|---|
| Safety variables (adverse events, vital signs, ECGs, clinical laboratory tests) | up to 50 days |
Countries
United Kingdom
Outcome results
None listed